PE20120535A1 - 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3 - Google Patents

3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3

Info

Publication number
PE20120535A1
PE20120535A1 PE2011001564A PE2011001564A PE20120535A1 PE 20120535 A1 PE20120535 A1 PE 20120535A1 PE 2011001564 A PE2011001564 A PE 2011001564A PE 2011001564 A PE2011001564 A PE 2011001564A PE 20120535 A1 PE20120535 A1 PE 20120535A1
Authority
PE
Peru
Prior art keywords
mercaptoquinoline
amino
quinolin
acetamide
alkyl
Prior art date
Application number
PE2011001564A
Other languages
English (en)
Spanish (es)
Inventor
Sven Kuhnert
Gregor Bahrenberg
Wolfgang Schroder
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20120535A1 publication Critical patent/PE20120535A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2011001564A 2009-03-10 2010-03-09 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3 PE20120535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09003431 2009-03-10

Publications (1)

Publication Number Publication Date
PE20120535A1 true PE20120535A1 (es) 2012-05-09

Family

ID=40591941

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001564A PE20120535A1 (es) 2009-03-10 2010-03-09 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3

Country Status (22)

Country Link
US (1) US8207342B2 (cg-RX-API-DMAC7.html)
EP (1) EP2406228B1 (cg-RX-API-DMAC7.html)
JP (1) JP5727945B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110130461A (cg-RX-API-DMAC7.html)
CN (1) CN102341374A (cg-RX-API-DMAC7.html)
AR (1) AR075730A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010223556B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1009519A2 (cg-RX-API-DMAC7.html)
CA (1) CA2754943A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011002160A1 (cg-RX-API-DMAC7.html)
CO (1) CO6410291A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011346A (cg-RX-API-DMAC7.html)
ES (1) ES2436365T3 (cg-RX-API-DMAC7.html)
IL (1) IL214944A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011009338A (cg-RX-API-DMAC7.html)
NZ (1) NZ595569A (cg-RX-API-DMAC7.html)
PE (1) PE20120535A1 (cg-RX-API-DMAC7.html)
PL (1) PL2406228T3 (cg-RX-API-DMAC7.html)
RU (1) RU2011140701A (cg-RX-API-DMAC7.html)
TW (1) TWI504395B (cg-RX-API-DMAC7.html)
WO (1) WO2010102779A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107370B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520246A (ja) * 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Kcnq2/3モジュレータとしての置換された3−アミノイソオキサゾロピリジン
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
DK2609083T3 (da) 2010-08-27 2015-03-30 Gruenenthal Gmbh Substituerede 2-oxy-quinolin-3-carboxamider som KCNQ2/3 modulatorer
WO2012025239A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
WO2012025237A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
MX2013002295A (es) 2010-09-01 2013-05-09 Gruenenthal Gmbh 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
DE102018212006B3 (de) 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
US5583147A (en) * 1994-03-23 1996-12-10 The Dupont Merck Pharmaceutical Company Amides for the treatment of atherosclerosis
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (en) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Arylthioacetamide derivatives
WO1999009983A1 (en) * 1997-08-28 1999-03-04 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
WO2001010380A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
CA2438231A1 (en) 2001-02-20 2002-08-29 Gene G. Kinney 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
EP1441722A2 (en) 2001-02-20 2004-08-04 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
EP1372654A4 (en) 2001-04-06 2007-10-03 Smithkline Beecham Corp QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES
BR0314390A (pt) 2002-09-17 2005-07-19 Pharmacia Corp Moduladores aromáticos dos receptores hepáticos x
AU2003303484C1 (en) 2002-12-23 2012-06-14 Icagen, Inc. Quinazolinones as potassium channel modulators
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
KR20060121909A (ko) 2003-10-08 2006-11-29 버텍스 파마슈티칼스 인코포레이티드 사이클로알킬 또는 피라닐 그룹을 포함하는 atp-결합카세트 수송자의 조절자
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
JP2008519814A (ja) 2004-11-12 2008-06-12 ガラパゴス・ナムローゼ・フェンノートシャップ プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
AU2006220130B2 (en) 2005-03-03 2011-07-28 H. Lundbeck A/S Substituted pyridine derivatives
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
WO2007015767A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
WO2007057447A1 (en) * 2005-11-18 2007-05-24 Neurosearch A/S Novel quinazoline derivatives and their medical use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
EP2057133B1 (en) 2006-07-20 2014-08-20 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
BRPI0814758A2 (pt) 2007-08-03 2015-03-03 Hoffmann La Roche Piridinacarboxamida e derivados de benzamida como ligantes taar1
WO2009052078A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
JP2012520246A (ja) 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Kcnq2/3モジュレータとしての置換された3−アミノイソオキサゾロピリジン
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier

Also Published As

Publication number Publication date
US20100234421A1 (en) 2010-09-16
EP2406228B1 (de) 2013-09-18
WO2010102779A1 (de) 2010-09-16
AU2010223556B2 (en) 2015-01-29
EP2406228A1 (de) 2012-01-18
NZ595569A (en) 2012-11-30
AR075730A1 (es) 2011-04-20
TWI504395B (zh) 2015-10-21
ES2436365T3 (es) 2013-12-30
KR20110130461A (ko) 2011-12-05
RU2011140701A (ru) 2013-04-20
AU2010223556A1 (en) 2011-11-03
TW201036610A (en) 2010-10-16
PL2406228T3 (pl) 2014-02-28
ECSP11011346A (es) 2011-10-31
JP5727945B2 (ja) 2015-06-03
CL2011002160A1 (es) 2012-08-17
MX2011009338A (es) 2011-09-27
JP2012521966A (ja) 2012-09-20
IL214944A0 (en) 2011-11-30
BRPI1009519A2 (pt) 2016-03-15
US8207342B2 (en) 2012-06-26
CO6410291A2 (es) 2012-03-30
CA2754943A1 (en) 2010-09-16
ZA201107370B (en) 2012-07-25
CN102341374A (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
PE20120535A1 (es) 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
GEP201706728B (en) Noxious organism control agent
EP2519977A4 (en) COST-EFFECTIVE, USING A MODIFICATOR OF CHALKOGENIZATION
EA201100037A1 (ru) Органические соединения
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
EA201001257A1 (ru) Модуляторы ampk (амф-активируемой протеинкиназы)
EA201100503A1 (ru) Глюкозидные производные и их применения
ATE459622T1 (de) Tropanverbindungen
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
TW201144306A (en) Bicyclic heteroaryl analogues as GPR119 modulators
CR10955A (es) Nuevo procedimiento de sintesis de la agomelatina
PH12012501853A1 (en) Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
IN2012DN00765A (cg-RX-API-DMAC7.html)
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
CY1116896T1 (el) Ανταγωνιστες του υποδοχεα trpm8
PE20071016A1 (es) Formas cristalinas de n-(benzo[b]tien-3-ilmetil)-sulfamida
EA201101097A1 (ru) Новые микробиоциды
UY31229A1 (es) Nuevo procedimiento de sintesis del (7-metoxi-1-naftil)acetonitrilo y aplicacion a la sintesis de la agomelatina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal